JP2016503407A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503407A5 JP2016503407A5 JP2015540965A JP2015540965A JP2016503407A5 JP 2016503407 A5 JP2016503407 A5 JP 2016503407A5 JP 2015540965 A JP2015540965 A JP 2015540965A JP 2015540965 A JP2015540965 A JP 2015540965A JP 2016503407 A5 JP2016503407 A5 JP 2016503407A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tocotrienol
- derivative
- tocopherol
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 40
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 29
- GJJVAFUKOBZPCB-UHFFFAOYSA-N 2-methyl-2-(4,8,12-trimethyltrideca-3,7,11-trienyl)-3,4-dihydrochromen-6-ol Chemical compound OC1=CC=C2OC(CCC=C(C)CCC=C(C)CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-UHFFFAOYSA-N 0.000 claims 29
- 229930003802 tocotrienol Natural products 0.000 claims 29
- 239000011731 tocotrienol Substances 0.000 claims 29
- 235000019148 tocotrienols Nutrition 0.000 claims 29
- 229930003799 tocopherol Natural products 0.000 claims 11
- 239000011732 tocopherol Substances 0.000 claims 11
- 229960001295 tocopherol Drugs 0.000 claims 11
- 235000010384 tocopherol Nutrition 0.000 claims 11
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims 11
- 229930003427 Vitamin E Natural products 0.000 claims 9
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 9
- 235000019165 vitamin E Nutrition 0.000 claims 9
- 239000011709 vitamin E Substances 0.000 claims 9
- 229940046009 vitamin E Drugs 0.000 claims 9
- 210000003296 saliva Anatomy 0.000 claims 8
- 238000000034 method Methods 0.000 claims 7
- 208000000112 Myalgia Diseases 0.000 claims 4
- 208000013465 muscle pain Diseases 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 208000024891 symptom Diseases 0.000 claims 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 230000003111 delayed effect Effects 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000009787 cardiac fibrosis Effects 0.000 claims 1
- 230000005189 cardiac health Effects 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000000087 stabilizing effect Effects 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018177662A JP6978392B2 (ja) | 2012-11-13 | 2018-09-21 | トコトリエノールの経粘膜送達 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2012904937A AU2012904937A0 (en) | 2012-11-13 | Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents | |
| AU2012904937 | 2012-11-13 | ||
| AU2012905406 | 2012-12-11 | ||
| AU2012905406A AU2012905406A0 (en) | 2012-12-11 | Sublingual and buccal delivery of tocotrienol derivatives as therapeutic agents | |
| PCT/AU2013/001310 WO2014075135A1 (en) | 2012-11-13 | 2013-11-13 | Transmucosal delivery of tocotrienol |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018177662A Division JP6978392B2 (ja) | 2012-11-13 | 2018-09-21 | トコトリエノールの経粘膜送達 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016503407A JP2016503407A (ja) | 2016-02-04 |
| JP2016503407A5 true JP2016503407A5 (enExample) | 2016-12-28 |
| JP6460998B2 JP6460998B2 (ja) | 2019-01-30 |
Family
ID=50730398
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540965A Active JP6460998B2 (ja) | 2012-11-13 | 2013-11-13 | トコトリエノールの経粘膜送達 |
| JP2018177662A Active JP6978392B2 (ja) | 2012-11-13 | 2018-09-21 | トコトリエノールの経粘膜送達 |
| JP2020171008A Pending JP2021008509A (ja) | 2012-11-13 | 2020-10-09 | トコトリエノールの経粘膜送達 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018177662A Active JP6978392B2 (ja) | 2012-11-13 | 2018-09-21 | トコトリエノールの経粘膜送達 |
| JP2020171008A Pending JP2021008509A (ja) | 2012-11-13 | 2020-10-09 | トコトリエノールの経粘膜送達 |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10675265B2 (enExample) |
| EP (1) | EP2919777B1 (enExample) |
| JP (3) | JP6460998B2 (enExample) |
| KR (1) | KR20150082109A (enExample) |
| CN (2) | CN104582700B (enExample) |
| AU (1) | AU2013344817B2 (enExample) |
| BR (1) | BR112015010703B1 (enExample) |
| CA (1) | CA2891164C (enExample) |
| DK (1) | DK2919777T3 (enExample) |
| ES (1) | ES2778065T3 (enExample) |
| IL (1) | IL238727A0 (enExample) |
| IN (1) | IN2015DN04006A (enExample) |
| MY (1) | MY177940A (enExample) |
| NZ (1) | NZ628963A (enExample) |
| PE (1) | PE20151518A1 (enExample) |
| PH (1) | PH12015501048A1 (enExample) |
| PL (1) | PL2919777T3 (enExample) |
| PT (1) | PT2919777T (enExample) |
| RU (1) | RU2015120181A (enExample) |
| SG (1) | SG11201503640WA (enExample) |
| WO (1) | WO2014075135A1 (enExample) |
| ZA (1) | ZA201504191B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9171343B1 (en) | 2012-09-11 | 2015-10-27 | Aseko, Inc. | Means and method for improved glycemic control for diabetic patients |
| US9897565B1 (en) | 2012-09-11 | 2018-02-20 | Aseko, Inc. | System and method for optimizing insulin dosages for diabetic subjects |
| RU2015120181A (ru) * | 2012-11-13 | 2017-01-10 | Гордаген Фармасьютикалз Пти Лтд | Чресслизистая доставка токотриенола |
| US9233204B2 (en) | 2014-01-31 | 2016-01-12 | Aseko, Inc. | Insulin management |
| US9486580B2 (en) | 2014-01-31 | 2016-11-08 | Aseko, Inc. | Insulin management |
| AU2015339576B2 (en) | 2014-10-27 | 2020-02-06 | Glytec, Llc | Subcutaneous outpatient management |
| US11081226B2 (en) | 2014-10-27 | 2021-08-03 | Aseko, Inc. | Method and controller for administering recommended insulin dosages to a patient |
| WO2017025808A1 (en) * | 2015-08-11 | 2017-02-16 | Satoru Sugiyama | System and method for improved blood circulation and maintaining mitochondrial energy production |
| EP3337402A4 (en) | 2015-08-20 | 2019-04-24 | Aseko, Inc. | THERAPY ADVISOR FOR DIABETES MANAGEMENT |
| US11612613B2 (en) | 2017-08-08 | 2023-03-28 | Robert Petcavich | Formulations for the delivery of autophagy stimulating Trehalose |
| US20240139100A1 (en) * | 2020-12-04 | 2024-05-02 | Invictus Biotechnology Pty Ltd | Transmucosal delivery of tocotrienols |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2124086A1 (en) * | 1991-11-22 | 1993-05-27 | Ronald H. Lane | Tocotrienols and tocotrienol-like compounds and methods for their use |
| JPH0892050A (ja) | 1994-09-27 | 1996-04-09 | Lion Corp | 消臭剤及び口腔用組成物 |
| JP4271742B2 (ja) | 1997-08-07 | 2009-06-03 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 免疫機能改善剤 |
| US6264981B1 (en) | 1999-10-27 | 2001-07-24 | Anesta Corporation | Oral transmucosal drug dosage using solid solution |
| US6864280B2 (en) * | 2000-03-31 | 2005-03-08 | Eisai Co., Ltd. | γ-Tocotrienol-containing diuretics |
| JP2001342133A (ja) | 2000-03-31 | 2001-12-11 | Eisai Co Ltd | γ―トコトリエノール含有利尿剤 |
| JP2002037727A (ja) | 2000-07-26 | 2002-02-06 | Eisai Co Ltd | 脂溶性薬物を配合した速崩性固形製剤及びその製造方法 |
| JP4693140B2 (ja) | 2000-10-06 | 2011-06-01 | 富士化学工業株式会社 | トコトリエノール含有医薬用剤 |
| JP4447198B2 (ja) | 2001-02-08 | 2010-04-07 | 富士化学工業株式会社 | トコトリエノールを有効成分とする血管新生阻害剤、細胞増殖阻害剤、管腔形成阻害剤及びｆｇｆ阻害剤並びに食品或いは食品添加物 |
| US6608103B2 (en) * | 2001-02-08 | 2003-08-19 | Fuji Chemical Industry Co., Ltd. | Inhibitor for neovasculation, cell multiplication, lumen formation and FGF |
| WO2004086412A2 (en) | 2003-02-14 | 2004-10-07 | Henry M. Jackson Foundation For The Advancement Of Military Medecine, Inc. | Radiation protection by gamma-tocotrienol |
| CA2521020C (en) * | 2003-04-10 | 2021-04-27 | Barrie Tan | Annatto extract compositions including tocotrienols and tocopherols and methods of use |
| US20050209315A1 (en) * | 2004-03-20 | 2005-09-22 | Papas Andreas M | Bioavailable nutritional supplement and method of treatment of malabsorption |
| US20060013901A1 (en) * | 2004-05-26 | 2006-01-19 | Kgk Synergize Inc. | Compositions comprising flavonoids and tocotrienols and methods thereof |
| CN1775289B (zh) | 2004-11-15 | 2011-08-24 | 杭州赛诺菲民生健康药业有限公司 | 多维生素口腔崩解片制剂及其制备方法 |
| EP2271347B1 (en) | 2008-03-28 | 2016-05-11 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine compositions |
| WO2009126866A2 (en) * | 2008-04-10 | 2009-10-15 | Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Delta-tocotrienol as a radioprotective countermeasure agent |
| MX2011012078A (es) | 2009-05-20 | 2012-03-14 | Lingual Consegna Pty Ltd | Formulacion terapeutica bucal y/o sublingual. |
| EA201200054A1 (ru) | 2009-06-25 | 2012-05-30 | Эмпэр Лайф Сайнсиз, Инк. | Лечение токотриенолами или экстрактами, богатыми токотриенолами, первазивных расстройств развития |
| HUE037592T2 (hu) * | 2009-08-26 | 2018-09-28 | Bioelectron Tech Corp | Eljárások cerebrális ischemia megelõzésére és kezelésére |
| EP2519232A1 (en) | 2009-12-31 | 2012-11-07 | Edison Pharmaceuticals, Inc. | Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones |
| EA201201374A1 (ru) * | 2010-04-06 | 2013-04-30 | Эдисон Фармасьютикалз, Инк. | Лечение атаксии-телеангиэктазии |
| WO2012068552A1 (en) * | 2010-11-19 | 2012-05-24 | Edison Pharmaceuticals, Inc. | Methods for improving blood glucose control |
| KR101796340B1 (ko) | 2011-02-18 | 2017-11-10 | 바이오링거스 아이피 엘엘씨 | 안정화된 활성제를 포함하는 생성물을 제조하는 방법 및 이를 포함하는 조성물 |
| EP2720699B1 (en) | 2011-06-14 | 2018-05-16 | Hale Biopharma Ventures, Llc | Administration of benzodiazepine |
| RU2015120181A (ru) * | 2012-11-13 | 2017-01-10 | Гордаген Фармасьютикалз Пти Лтд | Чресслизистая доставка токотриенола |
-
2013
- 2013-11-13 RU RU2015120181A patent/RU2015120181A/ru not_active Application Discontinuation
- 2013-11-13 EP EP13854440.8A patent/EP2919777B1/en active Active
- 2013-11-13 BR BR112015010703-6A patent/BR112015010703B1/pt active IP Right Grant
- 2013-11-13 NZ NZ628963A patent/NZ628963A/en unknown
- 2013-11-13 WO PCT/AU2013/001310 patent/WO2014075135A1/en not_active Ceased
- 2013-11-13 DK DK13854440.8T patent/DK2919777T3/da active
- 2013-11-13 PL PL13854440T patent/PL2919777T3/pl unknown
- 2013-11-13 ES ES13854440T patent/ES2778065T3/es active Active
- 2013-11-13 MY MYPI2015000856A patent/MY177940A/en unknown
- 2013-11-13 SG SG11201503640WA patent/SG11201503640WA/en unknown
- 2013-11-13 PE PE2015000622A patent/PE20151518A1/es not_active Application Discontinuation
- 2013-11-13 US US14/435,607 patent/US10675265B2/en active Active
- 2013-11-13 KR KR1020147022626A patent/KR20150082109A/ko not_active Withdrawn
- 2013-11-13 CN CN201380022566.8A patent/CN104582700B/zh active Active
- 2013-11-13 AU AU2013344817A patent/AU2013344817B2/en active Active
- 2013-11-13 CA CA2891164A patent/CA2891164C/en active Active
- 2013-11-13 JP JP2015540965A patent/JP6460998B2/ja active Active
- 2013-11-13 PT PT138544408T patent/PT2919777T/pt unknown
- 2013-11-13 CN CN202011457257.1A patent/CN112451518B/zh active Active
-
2015
- 2015-05-10 IL IL238727A patent/IL238727A0/en unknown
- 2015-05-11 IN IN4006DEN2015 patent/IN2015DN04006A/en unknown
- 2015-05-11 PH PH12015501048A patent/PH12015501048A1/en unknown
- 2015-06-10 ZA ZA2015/04191A patent/ZA201504191B/en unknown
-
2018
- 2018-09-21 JP JP2018177662A patent/JP6978392B2/ja active Active
-
2020
- 2020-04-23 US US15/929,297 patent/US11331302B2/en active Active
- 2020-10-09 JP JP2020171008A patent/JP2021008509A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016503407A5 (enExample) | ||
| RU2015120181A (ru) | Чресслизистая доставка токотриенола | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| JP2014528901A5 (enExample) | ||
| JP2014517050A5 (enExample) | ||
| RU2017114346A (ru) | АНТАГОНИСТЫ ИНТЕГРИНА ανβ6 | |
| JP2012193216A5 (enExample) | ||
| JP2015503593A5 (enExample) | ||
| JP2014528474A5 (enExample) | ||
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| BR112015010314A8 (pt) | composto ou sais farmaceuticamente aceitáveis ou isômeros dos mesmos, composição farmacêutica, secretagogo de insulina ou agente hipoglicêmico, agonista do receptor gpr40, e, método para tratar doenças ou distúrbios | |
| WO2008027854A3 (en) | Pharmaceutical compositions comprising hgh for oral delivery | |
| WO2015085143A3 (en) | Therapeutic agents for skin diseases and conditions | |
| JP2012502047A5 (enExample) | ||
| JP2019507786A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
| EA021395B1 (ru) | Комбинация инсулина с триазиновыми производными и их применение для лечения диабета | |
| JP2017508737A5 (enExample) | ||
| EP2514421A1 (en) | Composition comprising torasemide | |
| RU2021101120A (ru) | Сублингвальное или буккальное введение dim для лечения заболеваний кожи | |
| JP2021091608A5 (enExample) | ||
| JP2017530142A5 (enExample) | ||
| EA201590825A1 (ru) | Способы контролирования кровяного давления и снижения диспноэ при сердечной недостаточности |